Do you think FDA would accept improvement/less worsening in Fibrosis (as compared to SOC) via HRCT as a valid endpoint in IPF? I recall FDA didn't like FVC at first with Intermune (when CAPACITY results were presented at the panel). It would seem to me HRCT would be a more accurate measure of effect on the underlying disease.
Market Data 
Markets 
AI
